Pricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Net income margin (%)

RIBOMIC Inc.【JP:4591】

Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income margin (%) YoY (%)
Mar 31, 2025-48,359.7+1829.97%
Mar 31, 2023-2,505.7+20.34%
Mar 31, 2022-2,082.3+61.30%
Mar 31, 2021-1,290.9+83.27%
Mar 31, 2020-704.4-93.31%
Mar 31, 2019-10,524.9+804.65%
Mar 31, 2018-1,163.4+68.72%
Mar 31, 2017-689.5+160.00%
Mar 31, 2016-265.2-12458.11%
Mar 31, 20152.1-101.53%
Mar 31, 2014-140.1-14.50%
Mar 31, 2013-163.8+19.75%
Mar 31, 2012-136.8

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)